- The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Wednesday that Vas Narasimhan, Chief Executive of Novartis ( NYSE: NVS ) ( OTCPK:NVSEF ), assumed duties as the chair of the industry lobby’s director board.
- Narasimhan replaces Ramona Sequeira, president of Takeda’s ( TAK ) Global Portfolio Division, who served as PhRMA board chair since February 2022.
- “I’m eager to help lead the association at this pivotal moment for patients and our industry,” Narasimhan, who has led the Swiss pharma giant since 2018, said.
- Additionally, PhRMA announced that Daniel O’Day, the Chairman and CEO of Gilead Sciences ( GILD ), will serve as its board chair-elect , and Albert Bourla, the Chairman and CEO of Pfizer ( PFE ), will become its treasurer.
- PhRMA was in the news recently as Teva Pharmaceutical ( TEVA ) led the influential industry trade group following a similar move by AbbVie ( ABBV ) late last year.
For further details see:
Novartis CEO to lead top U.S. pharma lobby